Prova.ai raises $1.2M to predict ovarian cancer from mammograms
What's the deal? Prova.aiDealroom has a profile for this one. Try Dealroom → has raised $1.2 million in pre-seed funding from BioGeneratorDealroom has a profile for this one. Try Dealroom → and the Missouri Technology CorporationDealroom has a profile for this one. Try Dealroom →. The Washington UniversityDealroom has a profile for this one. Try Dealroom → spinout is building an AI model that analyses mammograms to estimate a woman's risk of developing ovarian cancer within five years.
What's the endgame? The company, founded by Joy Jiang and Graham Colditz, argues that breast imaging holds clues about a patient's broader health. "The breast tissue actually summarizes the past life exposure," Jiang told St. Louis Magazine, pointing to factors like age at first period, number of pregnancies, and lifestyle. Prova.ai combines that imaging with medical history to gauge cancer risk.
Why now? The startup builds directly on the founders' earlier company, PrognosiaDealroom has a profile for this one. Try Dealroom →, which used AI on mammograms to predict five-year breast cancer risk. They sold Prognosia to Seoul-based Lunit last year after it won FDA Breakthrough Device Designation.
The new funding will support further training of Prova.ai's model on mammography samples, expansion of its dataset, and preparation for FDA clearance.
What could go wrong? The approach remains early, and applying breast-imaging analysis to a different cancer is unproven. FDA clearance is still ahead, not secured.
The signal: At $1.2 million, the raise sits in the lower tier of funding rounds — modest capital for a hard clinical problem. But a proven founder team and a fresh application of a validated method make it a bet worth watching in cancer diagnostics.
Read more: femtechinsider.com
Image credit: Generated with Gemini
